Revision Date: February 2017
ICSI has endorsed with qualifications recommendations from two guidelines:
1. 2016 United States Preventive Services Task Force (USPSTF) recommendations on:
a. Primary prevention for adults age 40-75
2. 2013 American College of Cardiology (ACC) / American Heart Association (AHA) recommendations on:
a. Treatment targets
b. Secondary prevention,
c. Primary prevention for adults ≥ 21 years old with LDL ≥ 190 mg/dL
d. Statin Safety
e. Optimizing Statin Therapy
f. Monitoring Statin Therapy
g. Insufficient Response to Statin Therapy
ACC/AHA full citation:
Stone N, Robinson J, Lichtenstein A, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-2934.
USPSTF full citation:
US Preventive Services Task Force. JAMA 2016;316:1997-2007.
The American College of Cardiology (ACC), the American Heart Association (AHA), and the United States Preventive Services Task Force (USPSTF) are not sponsors of, affiliated with, nor do they endorse ICSI or the ICSI Lipids Management in Adults work group. ACC, AHA, and the USPSTF have not reviewed ICSI’s process for endorsement of guidelines. The following ICSI endorsement and conclusions are solely the consensus of the ICSI Lipid Management in Adults work group using the ICSI endorsement process.
Using the ICSI endorsement process, this document has been reviewed by the ICSI Lipid Management in Adults work group: Canoniero M, Kottke T, Baechler C, Fabian K, Kofron P, Leslie S, O’Connor P, Stewart S, Zerr B.
Please note, the previous ICSI Lipid Management in Adults guideline from November 2013 is being retired.